Description
Montiwar-F — Montelukast and Fexofenadine Together for Advanced Allergy Relief in Children
Montiwar-F combines Montelukast 4 mg with Fexofenadine 60 mg in a syrup formulation designed to address both the respiratory and allergic components of childhood allergic conditions. Montelukast works as a leukotriene receptor antagonist that reduces airway inflammation and helps manage symptoms associated with allergic rhinitis and asthma-related wheeze, while Fexofenadine acts as a non-sedating antihistamine that controls sneezing, itching and nasal congestion without causing drowsiness. This dual-mechanism approach makes Montiwar-F a practical choice for pediatricians managing children with seasonal or persistent allergic symptoms, giving franchise partners a clinically well-reasoned combination for their paediatric respiratory and allergy range.
Combination Consistency Backed by Certified Manufacturing
Lxir Medilabs is an ISO and WHO-GMP certified pharmaceutical company headquartered in Panchkula, Haryana with manufacturing carried out at our Baddi, Himachal Pradesh facility. Combining a leukotriene antagonist with a non-sedating antihistamine in a paediatric syrup requires careful formulation to maintain taste, stability and accurate dosing across every batch and Montiwar-F is manufactured under strict quality control to ensure this reliability. For a PCD pharma franchise company in India, offering a dependable dual-action allergy syrup gives field partners a strong product to introduce to pediatricians and allergists managing recurring allergic conditions in children.
Product Highlights for Franchise Partners
- Composition: Montelukast 4 mg + Fexofenadine 60 mg
- Dosage Form: Syrup
- Pack Size: 60 ML
- Pack Type: Plastic Bottle for easy dosing and storage
- Key Benefit: Advanced allergy relief for symptom control and better respiratory comfort
- Suited For: Distributors and medical representatives expanding their paediatric and respiratory range
Franchise partners looking to add a dual-action allergy syrup to their paediatric portfolio can explore this and other formulations through our PCD pharma franchise division, with complete promotional support.
Disclaimer: This is a paediatric product and should be used strictly as advised by a registered medical practitioner.
